Jane Street
ALXO icon

Jane Street’s ALX Oncology ALXO Stock Holding History

Jane Street’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,500
Closed -$23.2K – 11470
2025
Q4 		$23.2K Buy
+20,500
New +$31K ﹤0.01% 10696

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Jane Street's ALXO Position: Q1 2026 in Review

Jane Street reduced its ALX Oncology (ALXO) stake by 49% in Q1 2026, selling an estimated $173K and leaving 95,101 shares worth $191K. The position accounts for ﹤0.01% of the portfolio, ranked #10195.

Jane Street first reported a position in ALXO in Q3 2022 and has held it in 11 quarters since. The position peaked at $660K in Q1 2024. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Jane Street held 95,101 shares of ALX Oncology worth $191K as of Q1 2026.
  • Jane Street sold 90,860 ALX Oncology shares in Q1 2026, an estimated $173K.
  • ALX Oncology made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10195 holding.
  • Jane Street first reported a position in ALX Oncology in Q3 2022 and has held it in 11 quarters since.
  • Jane Street's ALX Oncology position peaked at $660K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.